Literature DB >> 23800747

A case report of disabling bone pain after long-term kidney transplantation.

T M M Myint1, M Vucak-Dzumhur, P R Ebeling, G J Elder.   

Abstract

A 77-year-old man, who received a renal transplant 13 years before for IgA glomerulonephritis, was referred after he developed bilateral mid-tibial aching pain that did not improve with simple analgesia. He had recently been changed from low-dose cyclosporine to tacrolimus, but the pain did not improve when this was reversed. He had a history of focal prostatic adenocarcinoma, cryptococcal lung infection, osteoporosis treated with alendronate for 2 years and multiple squamous cell carcinomas, including one requiring left neck dissection and radiotherapy. Upon physical examination, he had gouty tophi and marked bilateral tibial tenderness but had no other clinical findings. Laboratory investigations included an elevated intact parathyroid hormone value of 7.9 pmol/L (1.6 to 6.9), bone specific alkaline phosphatase of 22 µg/L (3.7 to 20.9), urinary deoxypyridinoline/creatinine ratio of 7.2 nmol/mmol (2.5 to 5.4) and C-reactive protein. Chest X-ray and tibial X-rays were normal, but there was marrow oedema and a prominent periosteal reaction on magnetic resonance imaging. A radionuclide bone scan showed increased symmetrical, linear uptake in both tibiae and the left femur, and uptake was also noted in both clinically asymptomatic humeri. Tibial bone biopsy disclosed small deposits of poorly differentiated metastatic cancer and a follow-up chest CT revealed a lung lesion. It was concluded that the bone pain and periostitis was caused by primary lung cancer with metastatic disease to bone, and an associated hypertrophic osteoarthropathy.

Entities:  

Mesh:

Year:  2013        PMID: 23800747     DOI: 10.1007/s00198-013-2425-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  14 in total

1.  Low-energy fractures of the humeral shaft and bisphosphonate use.

Authors:  Maria P Yavropoulou; Andrea Giusti; Sharita R Ramautar; Sander Dijkstra; Neveen A T Hamdy; Socrates E Papapoulos
Journal:  J Bone Miner Res       Date:  2012-06       Impact factor: 6.741

2.  Images in clinical medicine. Hypertrophic pulmonary osteoarthropathy and tripe palms.

Authors:  Hayder Saeed; Suleiman Massarweh
Journal:  N Engl J Med       Date:  2012-01-26       Impact factor: 91.245

Review 3.  Pachydermoperiostosis: an update.

Authors:  M Castori; L Sinibaldi; R Mingarelli; R S Lachman; D L Rimoin; B Dallapiccola
Journal:  Clin Genet       Date:  2005-12       Impact factor: 4.438

4.  Hypertrophic osteoarthropathy effectively treated with zoledronic acid.

Authors:  Melissa M King; Douglas A Nelson
Journal:  Clin Lung Cancer       Date:  2008-05       Impact factor: 4.785

Review 5.  From marrow oedema to osteonecrosis: common paths in the development of post-transplant bone pain.

Authors:  Grahame J Elder
Journal:  Nephrology (Carlton)       Date:  2006-12       Impact factor: 2.506

6.  Hypertrophic osteoarthropathy: endothelium and platelet function.

Authors:  F Silveri; R De Angelis; F Argentati; D Brecciaroli; S Muti; C Cervini
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

7.  Expression in lung carcinomas of platelet-derived growth factor and its receptors.

Authors:  T Kawai; S Hiroi; C Torikata
Journal:  Lab Invest       Date:  1997-11       Impact factor: 5.662

8.  Vascular endothelial growth factor and hypertrophic osteoarthropathy.

Authors:  L H Silveira; M Martínez-Lavín; C Pineda; M C Fonseca; C Navarro; A Nava
Journal:  Clin Exp Rheumatol       Date:  2000 Jan-Feb       Impact factor: 4.473

9.  Hypertrophic pulmonary osteoarthropathy demonstrated on SPECT/CT.

Authors:  Robert R Russo; Allen Lee; Robert Mansberg; Louise Emmett
Journal:  Clin Nucl Med       Date:  2009-09       Impact factor: 7.794

10.  Prostaglandin E2 and bone turnover markers in the evaluation of primary hypertrophic osteoarthropathy (pachydermoperiostosis): a case report.

Authors:  A Martínez-Ferrer; P Peris; Ll Alós; M Morales-Ruiz; N Guañabens
Journal:  Clin Rheumatol       Date:  2009-05-21       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.